化疗及靶向药物肝毒性的管理
Management of hepatotoxicity of chemotherapy and targeted agents.
作者信息
Mudd Todd William, Guddati Achuta Kumar
机构信息
Division of Hematology/Oncology, Georgia Cancer Center, Augusta University Augusta, GA 30912, USA.
出版信息
Am J Cancer Res. 2021 Jul 15;11(7):3461-3474. eCollection 2021.
Abstract
Hepatotoxicity of chemotherapeutic agents such as methotrexate, oxaliplatin, and irinotecan have been well documented and characterized allowing for careful management by oncologists during administration. However, the rapid advance of the field of oncology and introduction of new classes of therapies such as small molecule inhibitors and immunotherapies have introduced new hepatotoxicity challenges and management strategies. This work is a compilation of the hepatotoxicity and recommended management of various chemotherapies and targeted agents, with a focus on the newer classes of targeted anticancer agents.
摘要
甲氨蝶呤、奥沙利铂和伊立替康等化疗药物的肝毒性已得到充分记录和表征，使肿瘤学家在给药期间能够进行谨慎管理。然而，肿瘤学领域的迅速发展以及小分子抑制剂和免疫疗法等新型疗法的引入带来了新的肝毒性挑战和管理策略。这项工作汇编了各种化疗和靶向药物的肝毒性及推荐的管理方法，重点关注新型靶向抗癌药物。
相似文献
1
Management of hepatotoxicity of chemotherapy and targeted agents.化疗及靶向药物肝毒性的管理
Am J Cancer Res. 2021 Jul 15;11(7):3461-3474. eCollection 2021.
2
Cardiotoxicity of chemotherapy and targeted agents.化疗及靶向药物的心脏毒性
Am J Cancer Res. 2021 Apr 15;11(4):1132-1147. eCollection 2021.
3
Management of nephrotoxicity of chemotherapy and targeted agents: 2020.化疗和靶向药物肾毒性的管理：2020年
Am J Cancer Res. 2020 Dec 1;10(12):4151-4164. eCollection 2020.
4
Review article: colorectal cancer chemotherapy.综述文章：结直肠癌化疗
Aliment Pharmacol Ther. 2003 Oct 1;18(7):683-92. doi: 10.1046/j.1365-2036.2003.01735.x.
5
Infused chemotherapy use in the elderly after patent expiration.专利过期后老年人使用输注化疗药物。
Am J Manag Care. 2012 May 1;18(5):e173-8.
6
Virgin coconut oil supplementation attenuates acute chemotherapy hepatotoxicity induced by anticancer drug methotrexate via inhibition of oxidative stress in rats.补充初榨椰子油可通过抑制大鼠氧化应激来减轻抗癌药物甲氨蝶呤诱导的急性化疗肝毒性。
Biomed Pharmacother. 2017 Mar;87:437-442. doi: 10.1016/j.biopha.2016.12.123. Epub 2017 Jan 6.
7
Drug-Drug Interactions and Disease Status Are Associated With Irinotecan-Induced Hepatotoxicity: A Cross-Sectional Study in Shanghai.药物-药物相互作用和疾病状况与伊立替康诱导的肝毒性相关：上海的一项横断面研究。
J Clin Pharmacol. 2022 Sep;62(9):1160-1169. doi: 10.1002/jcph.2059. Epub 2022 May 6.
8
New oxaliplatin-based combinations in the treatment of colorectal cancer.新型奥沙利铂类药物联合方案治疗结直肠癌。
Colorectal Dis. 2003 Nov;5 Suppl 3:1-9. doi: 10.1046/j.1463-1318.5.s3.2.x.
9
Evaluating hepatotoxic effects of chemotherapeutic agents with gadoxetic-acid-enhanced magnetic resonance imaging.使用钆塞酸增强磁共振成像评估化疗药物的肝毒性作用。
Eur J Radiol. 2020 Mar;124:108807. doi: 10.1016/j.ejrad.2019.108807. Epub 2019 Dec 31.
10
Comparing time to disease progression of irinotecan and oxaliplatin-based chemotherapies in colorectal cancer patients with liver only metastasis.比较伊立替康和奥沙利铂为基础的化疗药物在仅有肝转移的结直肠癌患者中疾病进展时间的差异。
Am J Clin Oncol. 2013 Aug;36(4):388-91. doi: 10.1097/COC.0b013e318248da7c.
引用本文的文献
1
Tailoring oral targeted therapies dosage in lung cancer: A systematic review of pharmacokinetics studies on renal and hepatic impairment.肺癌口服靶向治疗药物剂量调整：关于肾和肝损伤的药代动力学研究的系统评价
PLoS One. 2025 Jul 29;20(7):e0324056. doi: 10.1371/journal.pone.0324056. eCollection 2025.
2
Aegeline improves doxorubicin-induced liver toxicity by modulating oxidative stress and Bax/Bcl2/caspase/NF-κB signaling.埃吉琳通过调节氧化应激和Bax/Bcl2/半胱天冬酶/NF-κB信号通路改善阿霉素诱导的肝毒性。
Sci Rep. 2025 Jul 26;15(1):27203. doi: 10.1038/s41598-025-09675-8.
3
The Modulatory Effects of Statins, Vitamin E, and Moringa Oleifera Extract on CD3 Expression in Ribociclib-Induced Hepatotoxicity in Rats.他汀类药物、维生素E和辣木提取物对瑞博西尼诱导的大鼠肝毒性中CD3表达的调节作用。
Acta Inform Med. 2025;33(2):90-95. doi: 10.5455/aim.2025.33.90-95.
4
Mitigation and management of adverse events associated with amivantamab therapy.与氨甲环酸治疗相关的不良事件的缓解与管理。 （注：你原文中“amivantamab”有误，正确的是“amivantamab-vmjw”，中文名为“氨甲环酸单抗”，这里按照你提供的错误名称翻译了，实际应用中请按正确名称处理。）
如果按照正确药物名称准确翻译为：与氨甲环酸单抗治疗相关的不良事件的缓解与管理。
Oncologist. 2025 Jul 4;30(7). doi: 10.1093/oncolo/oyaf194.
5
Acute Lymphoblastic Leukemia Presenting With Initial Hyperbilirubinemia and Significantly Elevated Liver Transaminases: A Rare Pediatric Case With Unadjusted Chemotherapy.以初始高胆红素血症和显著升高的肝转氨酶为表现的急性淋巴细胞白血病：一例未调整化疗方案的罕见儿科病例
Clin Med Insights Case Rep. 2025 Jun 26;18:11795476251351514. doi: 10.1177/11795476251351514. eCollection 2025.
6
Endothelial c-Myc and Doxorubicin-Induced Metabolic Alterations: A Multi-Organ Optical Imaging Study.内皮细胞c-Myc与阿霉素诱导的代谢改变：一项多器官光学成像研究
J Biophotonics. 2025 Apr 21:e70037. doi: 10.1002/jbio.70037.
7
Management of drug-induced liver injury associated with anti-cancer therapy.与抗癌治疗相关的药物性肝损伤的管理。
Front Physiol. 2025 Mar 27;16:1541020. doi: 10.3389/fphys.2025.1541020. eCollection 2025.
8
Steatosis is not associated with increased risk of chemotherapy-associated liver injury in metastatic colorectal cancer.在转移性结直肠癌中，肝脂肪变性与化疗相关肝损伤风险增加无关。
eGastroenterology. 2025 Mar 7;3(1):e100157. doi: 10.1136/egastro-2024-100157. eCollection 2025.
9
Drug-Induced Liver Injury-Pharmacological Spectrum Among Children.儿童药物性肝损伤的药理学谱
Int J Mol Sci. 2025 Feb 25;26(5):2006. doi: 10.3390/ijms26052006.
10
RNA nanotherapeutics for hepatocellular carcinoma treatment.用于治疗肝细胞癌的RNA纳米疗法。
Theranostics. 2025 Jan 1;15(3):965-992. doi: 10.7150/thno.102964. eCollection 2025.
本文引用的文献
1
Mechanism of hepatotoxicity of first-line tyrosine kinase inhibitors: Gefitinib and afatinib.一线酪氨酸激酶抑制剂（吉非替尼和阿法替尼）肝毒性的作用机制。
Toxicol Lett. 2021 Jun 1;343:1-10. doi: 10.1016/j.toxlet.2021.02.003. Epub 2021 Feb 8.
2
Nivolumab-Induced Autoimmune-Like Cholestatic Hepatitis in a Liver Transplant Recipient.一名肝移植受者中由纳武利尤单抗引起的自身免疫样胆汁淤积性肝炎
ACG Case Rep J. 2020 Jul 14;7(7):e00416. doi: 10.14309/crj.0000000000000416. eCollection 2020 Jul.
3
Safety and efficacy of chimeric antigen receptor (CAR)-T-cell therapy in persons with advanced B-cell cancers and hepatitis B virus-infection.嵌合抗原受体 (CAR)-T 细胞疗法在患有晚期 B 细胞癌症和乙型肝炎病毒感染的人群中的安全性和有效性。
Leukemia. 2020 Oct;34(10):2704-2707. doi: 10.1038/s41375-020-0936-4. Epub 2020 Jun 27.
4
Chemotherapy-associated liver injury in colorectal cancer.结直肠癌化疗相关肝损伤
Therap Adv Gastroenterol. 2020 May 20;13:1756284820924194. doi: 10.1177/1756284820924194. eCollection 2020.
5
Hepatotoxicity in patients with solid tumors treated with PD-1/PD-L1 inhibitors alone, PD-1/PD-L1 inhibitors plus chemotherapy, or chemotherapy alone: systematic review and meta-analysis.单独使用 PD-1/PD-L1 抑制剂、PD-1/PD-L1 抑制剂联合化疗或单纯化疗治疗实体瘤患者的肝毒性：系统评价和荟萃分析。
Eur J Clin Pharmacol. 2020 Oct;76(10):1345-1354. doi: 10.1007/s00228-020-02903-2. Epub 2020 Jun 8.
6
Factors affecting high-grade hepatotoxicity of tyrosine kinase inhibitors in cancer patients: a multi-center observational study.影响癌症患者酪氨酸激酶抑制剂发生高级别肝毒性的因素：一项多中心观察性研究。
Eur J Clin Pharmacol. 2020 Aug;76(8):1183-1191. doi: 10.1007/s00228-020-02897-x. Epub 2020 May 22.
7
Risk of hepatotoxicity with trastuzumab emtansine in breast cancer patients: a systematic review and meta-analysis.乳腺癌患者使用曲妥珠单抗-恩杂鲁胺的肝毒性风险：一项系统评价和荟萃分析。
Ther Adv Drug Saf. 2020 Apr 21;11:2042098620915058. doi: 10.1177/2042098620915058. eCollection 2020.
8
New molecular and biochemical insights of doxorubicin-induced hepatotoxicity.多柔比星诱导肝毒性的新分子和生化见解。
Life Sci. 2020 Jun 1;250:117599. doi: 10.1016/j.lfs.2020.117599. Epub 2020 Mar 29.
9
Characterization of risk factors and efficacy of medical management of immune-related hepatotoxicity in real-world patients with metastatic melanoma treated with immune checkpoint inhibitors.描述性分析：真实世界中接受免疫检查点抑制剂治疗的转移性黑色素瘤患者的免疫相关性肝毒性的风险因素和医学管理疗效。
Eur J Cancer. 2020 May;130:211-218. doi: 10.1016/j.ejca.2020.02.041. Epub 2020 Mar 28.
10
A case of severe hepatotoxicity induced by cisplatin and 5-fluorouracil.一例由顺铂和5-氟尿嘧啶引起的严重肝毒性病例。
Int Cancer Conf J. 2019 Nov 19;9(1):24-27. doi: 10.1007/s13691-019-00394-2. eCollection 2020 Jan.
Zotero 插件